We’ve recently updated our valuation analysis.

Regis Healthcare Valuation

Is REG undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for REG?

Other financial metrics that can be useful for relative valuation.

REG key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue0.9x
Enterprise Value/EBITDA13.6x
PEG Ration/a

Price to Sales Ratio vs Peers

How does REG's PS Ratio compare to its peers?

The above table shows the PS ratio for REG vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average1.4x
EHE Estia Health
0.8x5.2%AU$527.1m
MVF Monash IVF Group
2.2x8.1%AU$420.8m
PSQ Pacific Smiles Group
1.7x16.3%AU$231.4m
RHC Ramsay Health Care
1.1x4.9%AU$15.1b
REG Regis Healthcare
0.7x5.0%AU$510.0m

Price-To-Sales vs Peers: REG is good value based on its Price-To-Sales Ratio (0.7x) compared to the peer average (1.4x).


Price to Earnings Ratio vs Industry

How does REG's PE Ratio compare vs other companies in the AU Healthcare Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a5.1%
n/an/an/a

Price-To-Sales vs Industry: REG is good value based on its Price-To-Sales Ratio (0.7x) compared to the Australian Healthcare industry average (1.1x)


Price to Sales Ratio vs Fair Ratio

What is REG's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

REG PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.7x
Fair PS Ratio0.8x

Price-To-Sales vs Fair Ratio: REG is good value based on its Price-To-Sales Ratio (0.7x) compared to the estimated Fair Price-To-Sales Ratio (0.8x).


Share Price vs Fair Value

What is the Fair Price of REG when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: REG (A$1.7) is trading below our estimate of fair value (A$7.36)

Significantly Below Fair Value: REG is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst REG forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentAU$1.70
AU$2.25
+32.7%
20.2%AU$3.10AU$1.55n/a7
Jan ’24AU$1.89
AU$2.36
+25.3%
15.8%AU$3.10AU$1.95n/a7
Dec ’23AU$1.98
AU$2.36
+19.3%
15.8%AU$3.10AU$1.95n/a7
Nov ’23AU$2.05
AU$2.36
+15.2%
15.8%AU$3.10AU$1.95n/a7
Oct ’23AU$1.71
AU$2.37
+38.5%
15.6%AU$3.10AU$1.95n/a7
Sep ’23AU$2.03
AU$2.46
+21.3%
13.8%AU$3.10AU$2.15n/a6
Aug ’23AU$2.14
AU$2.47
+15.6%
12.9%AU$3.10AU$2.10n/a6
Jul ’23AU$1.82
AU$2.48
+36.4%
12.8%AU$3.10AU$2.10n/a6
Jun ’23AU$2.39
AU$2.48
+3.8%
12.8%AU$3.10AU$2.10n/a6
May ’23AU$2.10
AU$2.42
+15.4%
18.5%AU$3.24AU$2.10n/a5
Apr ’23AU$2.17
AU$2.42
+11.7%
18.5%AU$3.24AU$2.10n/a5
Mar ’23AU$2.12
AU$2.42
+14.3%
18.5%AU$3.24AU$2.10n/a5
Feb ’23AU$1.87
AU$2.38
+27.1%
16.0%AU$3.02AU$1.95AU$1.705
Jan ’23AU$1.87
AU$2.42
+29.2%
14.3%AU$3.02AU$1.89AU$1.896
Dec ’22AU$1.73
AU$2.49
+43.9%
10.5%AU$3.02AU$2.25AU$1.986
Nov ’22AU$1.95
AU$2.49
+28.0%
10.5%AU$3.02AU$2.25AU$2.056
Oct ’22AU$2.03
AU$2.49
+22.7%
10.5%AU$3.02AU$2.25AU$1.716
Sep ’22AU$2.17
AU$2.49
+14.7%
10.5%AU$3.02AU$2.25AU$2.036
Aug ’22AU$2.08
AU$2.43
+16.7%
15.6%AU$2.95AU$2.00AU$2.146
Jul ’22AU$1.97
AU$2.39
+21.9%
17.6%AU$2.95AU$1.80AU$1.826
Jun ’22AU$1.96
AU$2.36
+20.4%
18.7%AU$2.95AU$1.80AU$2.396
May ’22AU$2.30
AU$2.16
-5.9%
15.0%AU$2.83AU$1.80AU$2.106
Apr ’22AU$2.04
AU$2.14
+4.9%
14.3%AU$2.83AU$1.80AU$2.177
Mar ’22AU$1.99
AU$2.04
+2.6%
18.9%AU$2.83AU$1.36AU$2.128
Feb ’22AU$1.82
AU$1.79
-1.8%
15.0%AU$2.06AU$1.36AU$1.877

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies